NEW YORK (GenomeWeb) – Admera Health today announced that its PGxOne Plus and OncoGxOne molecular diagnostic tests have been approved for clinical use by the New Jersey Department of Health.
PGxOne is a companion diagnostic test to help predict response to therapy based on the patients' genetics. The gene panel, which assays 25 genes known to determine drug response, is an expanded version of Admera's PGxOne test.
OncoGxOne provides medically actionable genotyping results through the detection of all types of genetic variations, including point mutations, indels, gene fusions, and copy number variance, Admera's President Guanghui Hu said in a statement.
Both tests are based on next-generation sequencing technology.
South Plainfield, NJ-based Admera is a molecular diagnostics firm that is also developing non-invasive cancer tests, hereditary cardiovascular disease testing, and other disease-focused panels. The firm also provides EGFR and KRAS clinical sequencing services.
In October 2014, Admera signed a sales and marketing agreement with Rosetta Genomics for its tests and services.